ChiCTR-RNRC-11001425 版本V1.1 版本创建时间2015/07/12 20:25:55 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR-RNRC-11001425 

最近更新日期:

Date of Last Refreshed on:

2015-07-12 20:22:55 

注册时间:

Date of Registration:

2011-05-04 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

TLR4与新疆维吾尔族HIV相关型Kaposi's肉瘤相关性研究

Public title:

Association between TLR4 and HIV-related Kaposi’s sarcoma in Uyghur patients in Xinjiang

注册题目简写:

English Acronym:

研究课题的正式科学名称:

TLR4与新疆维吾尔族HIV相关型Kaposi's肉瘤相关性研究

Scientific title:

Association between TLR4 and HIV-related Kaposi’s sarcoma in Uyghur patients in Xinjiang

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

鲁晓擘 

研究负责人:

鲁晓擘 

Applicant:

Xiaobo LU 

Study leader:

Xiaobo LU 

申请注册联系人电话:

Applicant telephone:

+86 15999176213

研究负责人电话:

Study leader's telephone:

+86 15999176213

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

luxiaobo1101@sina.com

研究负责人电子邮件:

Study leader's E-mail:

luxiaobo1101@sina.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

新疆维吾尔自治区乌鲁木齐市鲤鱼山南路137

研究负责人通讯地址:

新疆维吾尔自治区乌鲁木齐市鲤鱼山南路137

Applicant address:

137 South Liyushan Road, Urumqi, Xinjiang, China

Study leader's address:

137 South Liyushan Road, Urumqi, Xinjiang, China

申请注册联系人邮政编码:

Applicant postcode:

830054

研究负责人邮政编码:

Study leader's postcode:

830054

申请人所在单位:

新疆医科大学第一附属医院

Applicant's institution:

First Affiliated Hospital of Xinjiang Medical University

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

20101203-3

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

新疆医科大学第一附属医院医学伦理委员会

Name of the ethic committee:

Ethic committee of first affiliated hospital of Xinjiang medical university

伦理委员会批准日期:

Date of approved by ethic committee:

2010-12-03 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

新疆医科大学第一附属医院

Primary sponsor:

First Affiliated Hospital of Xinjiang Medical University

研究实施负责(组长)单位地址:

新疆维吾尔自治区乌鲁木齐市鲤鱼山南路137

Primary sponsor's address:

137 South Liyushan Road, Urumqi, Xinjiang

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

国家自然基金会

具体地址:

北京市复兴路15号

Institution
hospital:

National Natural Science Foundation

Address:

15 Fuxing Rd, Beijing

经费或物资来源:

国家自然科学基金地区科学基金项目

Source(s) of funding:

Regional program of National natural science foundation

Target disease:

HIV-related Kaposi’s sarcoma

Target disease code:

研究类型:

病因学/相关因素研究

Study type:

Cause/Relative factors study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

非随机对照试验 

Study design:

Non randomized control 

研究目的:

验证TLR4的高表达是否抑制或阻止KS的生长或发生,为新疆KS与HIV相关型KS的防治提供新思路,为今后研发TLR4受体激动剂治疗KS奠定基础  

Objectives of Study:

To testify whether high expression of TLR4 can inhibit the growth and development of Kaposi’s sarcoma; to provide theoretical basis for the prevention and treatment of Kaposi’s sarcoma in Xinjiang and the therapy of TLR4 agonist for Kaposi’s sarcoma.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

AIDS相关性Kaposi's肉瘤患者、经典型Kaposi's肉瘤患者、HIV无Kaposi's肉瘤患者、健康者

Inclusion criteria

1. Uyghur patients with HIV-related Kaposi’s sarcoma;2. typical Kaposi's sarcoma;3. patient with HIV infection without Kaposi's sarcoma;4. Healthy people.

排除标准:

合并肝炎病毒感染者

Exclusion criteria:

Patient complicated with hepatitis.

研究实施时间:

Study execute time:

From 2011-01-01 00:00:00 To 2013-05-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2011-01-01 00:00:00 To 2012-06-30 00:00:00  

干预措施:

Interventions:

组别:

A

样本量:

30

Group:

A

Sample size:

干预措施:

HIV感染无KS患者

干预措施代码:

Intervention:

patients with HIV-related Kaposi’s sarcoma

Intervention code:

组别:

B

样本量:

30

Group:

B

Sample size:

干预措施:

HIV相关KS患者

干预措施代码:

Intervention:

HIV patients without Kaposi’s sarcoma

Intervention code:

组别:

C

样本量:

30

Group:

C

Sample size:

干预措施:

经典KS患者

干预措施代码:

Intervention:

calssical Kaposi’s sarcoma patients

Intervention code:

组别:

Control

样本量:

30

Group:

Control

Sample size:

干预措施:

健康者

干预措施代码:

Intervention:

heathy people

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

新疆维吾尔自治区 

市(区县):

 

Country:

China 

Province:

Xinjiang Uyghur Autonomous Region 

City:

 

单位(医院):

新疆医科大学第一附属医院 

单位级别:

三甲医院 

Institution
hospital:

First affiliated hospital of Xinjiang medical university

Level of the institution:

Tertiary A hospital

测量指标:

Outcomes:

指标中文名:

KS肿瘤组织及正常上皮组织

指标类型:

主要指标

Outcome:

Kaposi's sarcoma tissue and normal epithelia tissue

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 0 years
最大 Max age 0 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机数字表

Randomization Procedure (please state who generates the random number sequence and by what method):

randomization table

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

新疆医科大学第一附属医院

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Second division of infectious diseases, first affiliated hospital of Xinjiang medical university

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

新疆医科大学第一附属医院

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Second division of infectious diseases, first affiliated hospital of Xinjiang medical university

数据与安全监察委员会:

Data and Safety Monitoring Committee:

注册人:

Name of Registration:

 2015-07-12 20:22:55